Wells Fargo analyst Derek Archila raised the firm’s price target on Dice Therapeutics (DICE) to $48 from $38 and keeps an Equal Weight rating on the shares following news that Eli Lilly (LLY) will acquire the company for $48/share. The deal is expected to close in Q3 and the firm sees modest FTC risk to the deal given some small overlaps, but the deal likely gets done.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DICE:
- DICE Surges after $2.4 Billion Acquisition by LLY
- Eli Lilly to acquire Dice Therapeutics for $48 per share in cash
- Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
- DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
- DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights